Trial Profile
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Irinotecan (Primary)
- Indications Carcinoma; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Glioma; Medulloblastoma; Neuroblastoma; Neuroectodermal tumours; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- 01 Sep 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2023 Results(n=20) assessing effect of adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma published in the Cancer
- 28 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.